Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Medicine and Health Sciences
Is The Treatment Of Inflammatory Arthritis Different In Sickle Cell Disease?, Gezmi̇ş Ki̇myon, Gül İlhan
Is The Treatment Of Inflammatory Arthritis Different In Sickle Cell Disease?, Gezmi̇ş Ki̇myon, Gül İlhan
Turkish Journal of Medical Sciences
Background/aim: Musculoskeletal findings are common in sickle cell patients and may be confused with inflammatory arthritis. In addition, complications such as frequent infections may create difficulties while choosing drugs such as steroids, methotrexate, or antiTNFs. Our aim is to reveal whether the treatment is different in sickle cell patients with rheumatic diseases such as rheumatoid arthritis. Materials and methods: Patients followed by Rheumatology and Hematology divisions of Hatay Mustafa Kemal University Hospital were retrospectively screened. Excluding patients with musculoskeletal findings associated with sickle cell disease (SCD), patients with chronic or acute inflammatory arthritis were enrolled into study. Demographic data, disease …
Survival Of Biological Therapeutics In Psoriasis: Retrospective Analysis Of 3-Years Data In A Turkish Registry, Psortaksis, Kemal Özyurt, Gökmen Zararsiz, Ragip Ertaş, Ahu Cephe, Ömer Kutlu, Ömer Faruk Elmas, Muhammet Reşat Akkuş, Fatma Nur Kutlu, Mustafa Atasoy
Survival Of Biological Therapeutics In Psoriasis: Retrospective Analysis Of 3-Years Data In A Turkish Registry, Psortaksis, Kemal Özyurt, Gökmen Zararsiz, Ragip Ertaş, Ahu Cephe, Ömer Kutlu, Ömer Faruk Elmas, Muhammet Reşat Akkuş, Fatma Nur Kutlu, Mustafa Atasoy
Turkish Journal of Medical Sciences
Background/aim: PSORTAKSIS is a psoriasis registry, which is used for follow-up of patients in Kayseri City Education and Research Hospital, Dermatology Clinic since 2016 in Turkey. PSORTAKSIS includes demographic data, follow-up clinical findings, laboratory output, and treatment information of patients. Here, drug survivals of biologic therapeutics (BT) according to three-year data of PSORTAKSIS will be presented. Materials and methods: Drug survival of BT in PSORTAKSIS was analyzed from 2016 to March 2019. Results: 158 patients (111 of them BT-naive) with psoriasis under BT were enrolled in the current study. Drug survival analysis of patients with ongoing BT (158 treatment periods) …